Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Kane

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
The Canadian Journal of Urology|October 13, 2020
Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IVE David Crawford, Gerald Andriole, Stephen J Freedland, et al.
Cancer Immunology Research|October 1, 2016
Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate CancerXiao X Wei, Stephen Chan, Serena Kwek, et al.
Journal of Magnetic Resonance Imaging : JMRI|August 17, 2016
Restriction spectrum imaging: An evolving imaging biomarker in prostate MRIRyan L Brunsing, Natalie M Schenker-Ahmed, Nathan S White, et al.
Lancet (London, England)|March 13, 2016
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialNaomi B Haas, Judith Manola, Robert G Uzzo, et al.
Prostate Cancer and Prostatic Diseases|April 2, 2020
Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifierJeffrey J Tosoian, Samuel R Birer, R Jeffrey Karnes, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
The Canadian Journal of Urology|October 13, 2020
Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IVE David Crawford, Gerald Andriole, Stephen J Freedland, et al.
Cancer Immunology Research|October 1, 2016
Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate CancerXiao X Wei, Stephen Chan, Serena Kwek, et al.
Journal of Magnetic Resonance Imaging : JMRI|August 17, 2016
Restriction spectrum imaging: An evolving imaging biomarker in prostate MRIRyan L Brunsing, Natalie M Schenker-Ahmed, Nathan S White, et al.
Lancet (London, England)|March 13, 2016
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialNaomi B Haas, Judith Manola, Robert G Uzzo, et al.
Prostate Cancer and Prostatic Diseases|April 2, 2020
Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifierJeffrey J Tosoian, Samuel R Birer, R Jeffrey Karnes, et al.
Pageof 4